Peter Attia MD333 ‒ Longevity roundtable—the science of aging, geroprotective molecules, & lifestyle interventions
At a glance
WHAT IT’S REALLY ABOUT
Longevity Scientists Debate Aging Biology, Biomarkers, Funding, and Geroprotective Molecules
- Steven Austad, Richard Miller, and Matt Kaeberlein agree that aging is not a disease and that the booming public interest in longevity mixes real science with commercial hype.
- The panel disagrees on whether healthspan is a useful term, whether epigenetic age clocks have value, and how much to credit the hallmarks of aging and senescent cell research.
- They argue that aging research gets roughly half a percent of the NIH budget because of turf protection, a reactive disease-focused mindset, and political lobbying power.
- Miller proposes 'aging rate indicators' as a faster route to testing anti-aging interventions in humans, while Austad and Kaeberlein stress the difficulty of translating mouse findings and winning FDA acceptance.
- In a rapid review of specific interventions, rapamycin and canagliflozin look promising, metformin and GLP-1s remain open questions, resveratrol and NAD precursors lack evidence, and parabiosis or plasma exchange merits human testing.
IDEAS WORTH REMEMBERING
5 ideasAging should not be called a disease
Miller argues that aging is a risk factor for disease, and calling it a disease obscures that relationship; Kaeberlein agrees and Austad calls the label a marketing ploy to win funding.
Aging research is badly underfunded relative to its importance
Kaeberlein notes that nine of the top ten causes of death in the US have aging as their greatest risk factor, yet only about half of one percent of the NIH budget goes to the biology of aging.
Direct-to-consumer epigenetic age tests are unreliable
Kaeberlein tested four companies with duplicate samples and got ages from 42 to 63 against a chronological age of about 54. He concluded they are useful research tools but not clinical ones.
The hallmarks of aging helped and hurt the field
Kaeberlein says the framework helped communicate and legitimize mechanistic aging research, while Miller, Austad, and Kaeberlein say it narrowed funding and let lazy reviewers wave through proposals.
Aging rate indicators could speed human trials
Miller distinguishes biomarkers, like an odometer, from aging rate indicators, like a speedometer, and says about a dozen markers change in every slow-aging mouse, though this is unproven in people.
WORDS WORTH SAVING
5 quotesThe aging group has two lobbyists, one who's a lawyer and one who takes the calls, and it's not enough to do it.
— Richard Miller
If you look at the top 10 causes of death in the United States, nine of them have biological aging as their greatest risk factor, and it's not even close. Yet half of 1% of the research budget that's supposed to be focused on improving human health goes to study that risk factor.
— Matt Kaeberlein
The research flows from where the dollars are going. This has been seen over and over and over at NIH. You shift resource allocation to a certain area, and the scientists will follow.
— Matt Kaeberlein
An odometer is like a biomarker of aging of your car. It tells you how many miles your car has gone, but it doesn't tell you how fast the car is going. The speedometer tells you how fast your car is going.
— Richard Miller
I think it's the wrong question.
— Matt Kaeberlein
High quality AI-generated summary created from speaker-labeled transcript.
